Find Clinical Trials

Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter. If you would like help with this search, please contact us at patientsupport@clearityfoundation.org.

I want to filter the trials based on location, phase of development, or drug name, category or target
Mirvetuximab Soravtansine
No preference
No preference

Results

For more information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.

Clinical Trial Phase Eligible Participant Official Title Drugs in Trial Location
NCT02606305IbAdvanced FRalpha+ ovarian cancer (inc expansion)A Phase 1b/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Mirvetuximab Soravtansine (IMGN853) in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab+Carboplatin in Adults With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube CancerView DrugsMassachusetts, Ohio, Oklahoma, Pennsylvania
Drug(s) in Trial Other Drug Names Main Known Action
Mirvetuximab SoravtansineM9346A-sulfo-SPDB-DM4, IMGN853, Anti-FOLR1-mab Maytansinoid ConjugateADC: anti-FOLR1 + microtubule destabilizer (DM4)
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonist
CarboplatinParaplatin, NovoplatinumDNA damaging agent
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT02996825IPlatinum resistant FRalpha+ advanced ovarian cancer (< 5 prior therapies)A Phase I Dose-Escalation Safety and Tolerability Study of Mirvetuximab Soravtansine (IMGN853) and Gemcitabine in Patients With FRa-positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial Cancer, or Triple Negative Breast Cancer (TNBC)View DrugsCalifornia
Drug(s) in Trial Other Drug Names Main Known Action
Mirvetuximab SoravtansineM9346A-sulfo-SPDB-DM4, IMGN853, Anti-FOLR1-mab Maytansinoid ConjugateADC: anti-FOLR1 + microtubule destabilizer (DM4)
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitor
NCT03552471IAdvanced FRalpha+ ovarian cancer, except primary platinum-refractory (inc expansion)Phase I Study of Mirvetuximab Soravtansine (IMGN853) and Rucaparib for Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal CancerView DrugsOhio
Drug(s) in Trial Other Drug Names Main Known Action
Mirvetuximab SoravtansineM9346A-sulfo-SPDB-DM4, IMGN853, Anti-FOLR1-mab Maytansinoid ConjugateADC: anti-FOLR1 + microtubule destabilizer (DM4)
RucaparibAG-014699, PF 01367338, CO-338, RubracaPARP inhibitor